----

----

|     Colorado                                    |   | 84-1509950                        |
|---------------------------------------------------------------------|--------|-----------------------------------|
| (State or other jurisdictionof incorporation or organization)  |   | (IRS Employer Identification No.) |

----

| PART I.    FINANCIAL INFORMATION                                                                                   |   |
|----------------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                                   |   |
| Item 1.      Consolidated Financial Statements                                                                | 3      |
|                                                                                                                                   |   |
| Consolidated Balance Sheet                                                                                                             | 3      |
|                                                                                                                                   |   |
| Consolidated Statements of Operations,                                                                                                 | 5      |
|                                                                                                                                   |   |
| Consolidated Statements of Cash Flows                                                                                                  | 6      |
|                                                                                                                                   |   |
| Consolidated Statements of Comprehensive Loss                                                                                          | 7      |
|                                                                                                                                   |   |
| Consolidated Statement of Stockholders’ (Deficit)                                                                                | 8      |
|                                                                                                                                   |   |
| Notes to Unaudited Consolidated Financial Statements                                                                                   | 9      |
|                                                                                                                                   |   |
| Item 2.       Management's Discussion and Analysis of Financial Condition and Results of Operations | 13     |
|                                                                                                                                   |   |
| Item 3.       Quantitative and Qualitative Disclosures About Market Risk                            | 18     |
|                                                                                                                                   |   |
| Item 4T.       Controls and Procedures                                                              | 18     |
|                                                                                                                                   |   |
| Part II. OTHER INFORMATION                                                                                                             |   |
|                                                                                                                                   |   |
| Item 1        Legal Proceedings                                                                | 19     |
|                                                                                                                                   |   |
| Item 1A.    Risk Factors                                                                                                | 19     |
|                                                                                                                                   |   |
| Item 2.       Unregistered Sales of Equity Securities and Use of Proceeds                           | 19     |
|                                                                                                                                   |   |
| Item 3.       Defaults upon Senior Securities                                                       | 19     |
|                                                                                                                                   |   |
| Item 4.       (Removed and Reserved)                                                                | 19     |
|                                                                                                                                   |   |
| Item 5.       Other Information                                                                          | 19     |
|                                                                                                                                   |   |
| Item 6.       Exhibits                                                                              | 19     |
|                                                                                                                                   |   |
| SIGNATURES                                                                                                                             | 20     |
|                                                                                                                                   |   |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

|              |   | December 31,2010 |     |   | September 30,2010 |   |
|--------------------------------------------------------------------------|--------|------------------|----------|--------|-------------------|--------|
|                                                                     |   | (Unaudited)      |     |   | (Audited)         |   |
| Assets                                                                   |   |             |     |   |              |   |
| Current Assets                                                           |   |             |     |   |              |   |
| Cash and cash equivalents                                                |   | $                | 14,756   |   |              | $      | 26,716 |   |
| Accounts receivable                                                      |   |             | 13,569   |   |              |   | 12,809 |   |
| Inventories                                                              |   |             | 226,839  |   |              |   | 224,223 |   |
| Prepaid expenses                                                         |   |             | 19,781   |   |              |   | 20,200 |   |
|                                                                     |   |             |     |   |              |   |   |   |
| Total Current Assets                                                     |   |             | 274,945  |   |              |   | 283,948 |   |
|                                                                     |   |             |     |   |              |   |   |   |
|                                                                     |   |             |     |   |              |   |   |   |
| Long Term Investment                                                     |   |             |     |   |              |   |   |   |
| Investment in MIT China Joint Venture                                    |   |             | 322,752  |   |              |   |      348,434 |   |
|                                                                     |   |             |     |   |              |   |   |   |
| Property and Equipment                                                   |   |             |     |   |              |   |   |   |
| Tooling and machinery                                                    |   |             | 315,263  |   |              |   | 301,995 |   |
| Furniture and office equipment                                           |   |             | 146,611  |   |              |   | 141,600 |   |
| Leasehold improvements                                                   |   |             | 30,163   |   |              |   | 29,132 |   |
|                                                                     |   |             | 492,037  |   |              |   | 472,727 |   |
|                                                                     |   |             |     |   |              |   |   |   |
| Less accumulated depreciation                                            |   |             | (453,707 | )      |              |   | (451,779 | ) |
|                                                                     |   |             | 38,330   |   |              |   | 20,948 |   |
| Other Assets                                                             |   |             |     |   |              |   |   |   |
| Patents (net of accumulated amortization of $3,987 and $4,372)           |   |             | 20,780   |   |              |   | 14,834 |   |
|      Total assets                               |   | $                | 656,807  |   |              | $      | 668,164 |   |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

|                                                                             |   |
|----------------------------------------------------------------------------------|--------|
| CONSOLIDATED BALANCE SHEET                                                       |   |
|                                                                             |   |
|                                                                             |   |   |   |   |   |   |
|                                                                             |   | December 31 2010 |   |   | September 30 2010 |   |
|                                                                             |   | (Unaudited) |   |   | (Audited) |   |
| Liabilities and Stockholders' Equity (Deficit)                                   |   |   |   |   |   |   |
| Current Liabilities                                                              |   |   |   |   |   |   |
|         Deferred income                       |   |  $ | 1,105,961 |   |   |  $ | 1,078,009 |   |
|         Accounts payable and accrued expenses |   |   | 179,216 |   |   |   | 312,303 |   |
|         Amounts due to related parties        |   |   | 182,262 |   |   |   | 178,767 |   |
|                                                                             |   |   |   |   |   |   |   |   |
|                                                                             |   |   | 1,467,439 |   |   |   | 1,569,079 |   |
|                                                                             |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |
| Total Liabilities                                                                |   |   | 1,467,439 |   |   |   | 1,569,079 |   |
|                                                                             |   |   |   |   |   |   |   |   |
| Stockholders' Equity (Deficit)                                                   |   |   |   |   |   |   |   |   |
| Preferred stock, $.0001 par value; 3,000,000 shares authorized;                  |   |   |   |   |   |   |   |   |
| None issued and outstanding as of December 31, 2007                              |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |
| Common stock, $.0001 par value; 100,000,000 shares authorized;                   |   |   |   |   |   |   |   |   |
| 68,030,295 and 66,260,295 shares issued and                                      |   |   |   |   |   |   |   |   |
| Outstanding, respectively                                                        |   |   | 6,774 |   |   |   | 6,626 |   |
|                                                                             |   |   |   |   |   |   |   |   |
| Additional paid-in capital                                                       |   |   | 12,109,596 |   |   |   | 11,931,996 |   |
| Deficit                                                                          |   |   | (12,490,320 | ) |   |   | (12,418,732 | ) |
| Other comprehensive income (loss)                                                |   |   | (436,682 | ) |   |   | (420,805 | ) |
|                                                                             |   |   |   |   |   |   |   |   |
| Total Stockholders' Equity (Deficit)                                             |   |   | (810,632 | ) |   |   | (900,915 | ) |
|                                                                             |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |
| Total Liabilities and Stockholders' Equity (Deficit)                             |   |  $ | 656,807 |   |   | $ | 668,164 |   |
|                                                                             |   |   |   |   |   |   |   |   |
|                                                                             |   |   |   |   |   |   |   |   |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

|                                                                    |   | Three-Months PeriodEnded December 31, |       |
|-------------------------------------------------------------------------|--------|---------------------------------------|------------|
|                                                                    |   | 2010(Unaudited)                       |       |   | 2009(Unaudited) |   |
| Sales                                                                   |   | $                                     | 65,185     |   |   | $ | 208,563 |   |
| Cost of sales                                                           |   |                                  | (26,442    | ) |   |   | (54,991 | ) |
| Gross profit (loss)                                                     |   |                                  | 38,743     |   |   |   | 153,572 |   |
|                                                                    |   |                                  |       |   |   |   |   |   |
| Research and development costs                                          |   |                                  |       | - |   |   | (152,437 | ) |
| Selling, general, and administrative expenses                           |   |                                  | (83,961    | ) |   |   | (283,274 | ) |
|                                                                    |   |                                  | (83,961    | ) |   |   | (435,741 | ) |
|                                                                    |   |                                  |       |   |   |   |   |   |
|  Loss from operations                                              |   |                                  | (45,218    | ) |   |   | (282,169 | ) |
|                                                                    |   |                                  |       |   |   |   |   |   |
| Other Income (Expense)Equity earnings (loss) on MIT China Joint Venture |   |                                  | (25,682)   |   |   |   | -  |   |
| Interest                                                                |   |                                  | -          |   |   |   | 588 |   |
| Interest expense                                                        |   |                                  | (687       | ) |   |   | (6,244 | ) |
|                                                                    |   |                                  | (26,369    | ) |   |   | (5,656) |   |
|                                                                    |   |                                  |       |   |   |   |   |   |
|                                                                    |   |                                  |       |   |   |   |   |   |
|                                                                    |   |                                  |       |   |   |   |   |   |
| Net Loss                                                                |   | $                                     | (71,587    | ) |   | $ | (287,825 | ) |
|                                                                    |   |                                  |       |   |   |   |   |   |
| Basic (loss) per share                                                  |   | $                                     | (0.001     | ) |   | $ | (0.005 | ) |
|                                                                    |   |                                  |       |   |   |   |   |   |
| Basic weighted average shares outstanding                               |   |                                  | 68,030,295 |   |   |   | 60,357,795 |   |
|                                                                    |   |                                  |       |   |   |   |   |   |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

|                                                                                        |   | Three-Month Period Ended |                                                                |
|---------------------------------------------------------------------------------------------|--------|--------------------------|---------------------------------------------------------------------|
|                                                                                        |   | Dec 31,                  |                                                                |   | Dec 31, |   |
|                                                                                        |   | 2010                     |                                                                |   | 2009 |   |
| Cash flows from operating activities:                                                       |   |                     |                                                                |   |   |   |
| Net loss                                                                                    |   | $                        | (71,587                                                             | ) |   | $ | (287,825 | ) |
| Adjustments to reconcile net loss to net cash                                               |   |                     |                                                                |   |   |   |   |   |
|   provided by (used in) operating activities:                                     |   |                     |                                                                |   |   |   |   |   |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
|     Equity loss from MIT China Joint Venture                            |   |                     | 25,682                                                              |   |   |   |                                - |   |
|     Depreciation and amortization expense                               |   |                     | 6,048                                                               |   |   |   | 5,043 |   |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
|     Common stock issued for services                                    |   |                     | 1,000                                                               |   |   |   | 123,000 |   |
|     Related party payables settle by common stock                       |   |                     |            - |   |   |   |        - |   |
|     Capitalization of related party debts                               |   |                     |                                                                |   |   |   |   |   |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
| Changes in:                                                                                 |   |                     |                                                                |   |   |   |   |   |
|     Accounts receivable                                                 |   |                     | (760                                                                | ) |   |   | 1,815 |   |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
|     Inventories                                                         |   |                     | (2,616                                                              | ) |   |   | (21,935 | )  |
|     Prepaid expenses                                                    |   |                     | 419                                                                 |   |   |   | (311 | ) |
|     Accounts payable and accrued liabilities                            |   |                     | (133,087                                                            | ) |   |   | 67,750 |   |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
|     Deferred income                                                     |   |                     | 27,952                                                              |   |   |   | (27,057 | ) |
|          Net cash used by operating activities |   |                     | (146,949                                                            | ) |   |   | (139,520 | ) |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
| Cash flows from investing activities:                                                       |   |                     |                                                                |   |   |   |   |   |
|     Acquisition of patents                                              |   |                     | (2,134                                                              | ) |   |   | - |   |
|     Investment in MIT China joint venture                               |   |                     | -                                                                   |   |   |   | (10,437 | ) |
|     Tooling and machinery                                               |   |                     | (2,580                                                              | )  |   |   | - |   |
|         Net cash used by investing activities       |   |                     | (4,714                                                              | ) |   |   |       (10,437 | ) |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
| Cash flows from financing activities:                                                       |   |                     |                                                                |   |   |   |   |   |
|    Proceeds from issuance of stock, net                                      |   |                     | 158,017                                                             |   |   |   | - |   |
|    Increase in amounts due to related parties                                |   |                     | 3,495                                                               |   |   |   | 221,519 |   |
|    Issuance of notes payable                                                 |   |                     | -                                                                   |   |   |   | - |   |
|    Repayment on notes payable                                                |   |                | -                                                                   |   |   |    |        (1,701 | ) |
|         Net cash provided from financing activities |   |                     | 161,512                                                             |   |   |   | 219,818 |   |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
| Effect of exchange rates                                                                    |   |                     | (21,809                                                             | ) |   |   | (64,674 | )  |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
|                                                                                        |   |                     |                                                                |   |   |   |   |   |
| Increase (decrease) in cash                                                                 |   |                     | (11,960                                                             | )  |   |   | 5,188 |   |
| Cash, beginning of period                                                                   |   |                     | 26,716                                                              |   |   |   | 77,461 |   |
| Cash, end of period                                                                         |   | $                        | 14,756                                                              |   |   | $ | 82,648 |   |
| Supplemental disclosure of cash flow information:                                           |   |                     |                                                                |   |   |   |   |   |
|     Cash paid for interest                                              |   | $                        | 687                                                                 |   |   | $ | 6,244 |   |
|     Cash paid for federal income taxes                                  |   | $                        | -                                                                   |   |   | $ | - |   |
| Supplemental disclosure of non-cash transactions                                            |   |                     |                                                                |   |   |   |   |   |
|    Common stock issued for debt reductions                                   |   | $                        | -                                                                   |   |   | $ | - |   |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

|                                                                 |   |
|----------------------------------------------------------------------|--------|
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS                        |   |
|                                                                 |   | Three Months EndedDec 31,2010 |   |   | Three Months EndedDec 31,2009 |   |
| Net loss                                                             |   | $ | (71,587 | ) |   | $ | (287,825 | ) |
| Other comprehensive income (loss)                                    |   |   |   |   |   |   |   |   |
| Foreign currency translation adjustment                              |   |   | (15,877) |   |   |   | (63,548) |   |
|                                                                 |   |   |   |   |   |   |   |   |
|        Net comprehensive income (loss) |   | $ | (87,464 | ) |   | $ | (351,373 | ) |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

|                                                    |   |
|---------------------------------------------------------|--------|
|                                                    |   |
| CONSOLIDATED STATEMENT OF STOCKHOLDERS’ (DEFICIT) |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                    |   | Common Stock |   |   | Additional Paid in |   |
|                                                    |   | Shares |   |   | Amount |   |   | Capital |   |   | Deficit |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance – September 30, 2010                      |   |   | 66,260,295 |   |   | $ | 6,626 |   |   | $ | 11,931,996 |   |   | $ | (12,418,733 | ) |
|                                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shares issued for debts                                 |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
| Shares issued for services                              |   |   | 10,000 |   |   |   | 1 |   |   |   | 999 |   |   |   | - |   |
| Shares issued for additional capital                    |   |   | 1,760,000 |   |   |   | 147 |   |   |   | 176,601 |   |   |   | - |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss for the period ended December 31, 2010         |   |   | - |   |   |   | - |   |   |   | - |   |   |   | (71,587 | ) |
|                                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   | - |   |
| Balance – December 31, 2010                       |   |   | 68,030,295 |   |   |   | 6,774 |   |   |   | 12,109,596 |   |   |   | (12,490,320 | ) |
|                                                    |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

|            |   | December 31,2010 |    |   | September 30,2010 |   |
|-----------------|--------|------------------|---------|--------|-------------------|--------|
| Raw materials   |   | $                | 170,271 |   |              | $      | 166,611 |   |
| Work in process |   |             | 46,998  |   |              |   | 47,259 |   |
| Finished goods  |   |             | 9,569   |   |              |   | 10,353 |   |
| Total           |   | $                | 226,838 |   |              | $      | 224,223 |   |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

|    |   | GrossIntangibleAssets |   |   | Accumulated Amortization |   |   | Net IntangibleAssets |   | WeightedAverageLife(Years) |
|---------|--------|-----------------------|--------|--------|--------------------------|--------|--------|---------------------------|--------|----------------------------|
| Patents |   | $                     | 24,767 |   |                     | $      | 3,987  |                      |   | $                          | 20,780 |   | 8.5 through 16 |

|                            |   | December 31,2010 |    |   | September 30,2010 |   |
|---------------------------------|--------|------------------|---------|--------|-------------------|--------|
| Payable to 2849-674 Canada Inc  |   | $                | 70,380  |   |              | $      | 67,974 |   |
| Payable to Pascal D'Onofrio     |   |             | 31,882  |   |              |   |          30,793 |   |
| Payable to 9211-0766 Quebec Inc |   |             | 80,000  |   |              |   |          80,000 |   |
|                            |   |             |    |   |              |   |   |   |
|                            |   | $                | 182,262 |   |              | $      | 178,767 |   |

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

----

| Medical International Technology, Inc. |  Quarterly Financial Report |
|----------------------------------------|----------------------------------|

----

----

----

----

----

----

----

----

|                                                  | Medical International Technology, Inc. |                                          |
|-------------------------------------------------------|----------------------------------------|-----------------------------------------------|
|                                                  |                                   |                                          |   |
| Date: February 17, 2011      | By:                                    | /s/ Karim Menassa                   |   |
|                                                  |                                   | Karim Menassa                                 |   |
|                                                  |                                   | President and Principal Executive Officer     |   |
|                                                  |                                   | Interim Secretary and Chief Financial Officer |   |

----